Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

por MacNeil, Ian A., Khan, Salmaan A., Sen, Adrish, Soltani, Sajjad M., Burns, David J., Sullivan, Brian F., Laing, Lance G.
Publicado 2022

Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells

por Huang, Yao, Burns, David J., Rich, Benjamin E., MacNeil, Ian A., Dandapat, Abhijit, Soltani, Sajjad M., Myhre, Samantha, Sullivan, Brian F., Lange, Carol A., Furcht, Leo T., Laing, Lance G.
Publicado 2017

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

por MacNeil, Ian A., Burns, David J., Rich, Benjamin E., Soltani, Sajjad M., Kharbush, Samantha, Osterhaus, Nicole G., Sullivan, Brian F., Hawkins, Douglas M., Pietruska, Jodie R., Laing, Lance G.
Publicado 2020

A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity

por Huang, Yao, Burns, David J, Rich, Benjamin E, MacNeil, Ian A, Dandapat, Abhijit, Soltani, Sajjad M., Myhre, Samantha, Sullivan, Brian F, Furcht, Leo T, Lange, Carol A, Hurvitz, Sara A, Laing, Lance G
Publicado 2016